NCT03356860View on ClinicalTrials.gov

Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer.

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

April 13, 2017

Primary Completion Date

November 21, 2022

Study Completion Date

December 31, 2023

Conditions
Breast CancerTriple Negative Breast CancerLuminal B
Interventions
DRUG

Paclitaxel

80mg/m2 IV weekly from week 1 to week12

DRUG

Epirubicin

90 mg/m2 IV Q 2 weeks from week 14 to week 20

DRUG

Cyclophosphamide

600 mg/m2 IV Q 2 weeks from week 14 to week 20

DRUG

Durvalumab

Durvalumab 1500 mg IV at week 14 and 18

Trial Locations (4)

1320

Cliniques universitaires St Luc, Brussels

5000

CHU UCL Namur - Sainte-Elisabeth, Namur

5530

CHU UCL Namur - Site Godinne, Yvoir

6000

Grand Hôpital de Charleroi, Charleroi

All Listed Sponsors
collaborator

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

OTHER

lead

Grand Hôpital de Charleroi

OTHER

NCT03356860 - Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer. | Biotech Hunter | Biotech Hunter